A cross-species drug hunt posts notable negatives on rapamycin and metformin

Edited by Samael A. Tejada, Founder & Editor-in-Chief

A new cross-species drug-discovery paper systematically hunted for lifespan-extending compounds across yeast, worms, flies and killifish — with unusually rigorous artifact hunting — and published striking negative results: rapamycin and metformin failed to extend life in killifish, and metformin and resveratrol failed in mice, as reported September 22, 2026.

Why does this matter for mitochondrial health?

Both rapamycin and metformin act on mitochondrial and metabolic pathways — metformin engages mitochondrial complex I, and rapamycin modulates nutrient-sensing networks that govern mitochondrial quality control. When the field's most-discussed longevity drugs fail in a vertebrate model, it reshapes how seriously we take animal-model hype for mitochondrial and longevity interventions alike.

Are negative results really news?

Yes. Longevity media rarely reports what didn't work. Negative, well-controlled results protect readers from the "everything extends lifespan in something" fog and keep attention on interventions with reproducible cross-species evidence.

Where the evidence stands

• Established: The negative lifespan results were published and publicly reported; the screen's methods were designed to catch common artifacts.
• Preliminary: Why the compounds failed in killifish while working in other models remains open biology.
• Contested: Whether killifish results generalize to mammals or humans is debated; the paper itself does not claim human relevance.